Davide Campari-Milano (CPR) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
4 Mar, 2026Executive summary
Achieved organic top-line growth of 2.4% year-over-year in 2025, with reported net sales at €3,051 million, driven by growth in 24 countries and all brand houses despite FX headwinds and portfolio streamlining.
EBIT-adjusted rose by 5.3% to €637 million, with margin accretion of 60 basis points, supported by gross margin gains and cost containment.
Net profit-adjusted increased by 2.7% to €386 million; reported net profit surged 71.7% to €346 million due to lower operating adjustments and one-off items.
Outperformed in key markets, gaining share in nearly every region, especially in the U.S. on-premise channel and EMEA.
Leverage ratio improved to 2.5x, a year ahead of plan, supported by strong cash generation and disciplined capital allocation.
Financial highlights
Organic net sales growth of 2.4% year-over-year; reported sales down 0.6% due to FX (-3.0%) and minor perimeter impact (+0.1%).
Adjusted EBIT reached €637 million (+5.3% year-over-year), with margin up 60bps to 20.9%; gross margin up 100bps, mainly from input cost benefits.
EBITDA-adjusted at €785 million (+7.2%), with margin at 25.7%.
Adjusted net profit at €386 million (+2.7%); reported net profit at €346 million (+71.7%).
Recurring free cash flow conversion at 73% (FCF at €571 million); net financial debt reduced by €419 million year-over-year to €1,958 million.
Outlook and guidance
Targeting mid- to high single-digit organic top-line growth in the medium term, with continued margin accretion and strong cash generation.
2026 profitability expected to be H2-weighted due to front-loaded A&P and €30 million tariff impact; gross margin to see limited expansion.
Negative perimeter effect of €70 million on topline and €30 million on EBIT-adjusted expected from non-core brand disposals.
SG&A containment program to deliver cumulative 200bps benefit by end-2027.
Dividend per share up 54% to €0.10 (35% payout ratio), with further increases possible as deleverage continues.
Latest events from Davide Campari-Milano
- Solid H1 growth led by Americas and Global Priorities, with margin pressure from mix and capex.CPR
Q2 20242 Feb 2026 - Net sales up 2.1% YTD, EBIT margin down, with cost cuts, acquisitions, and portfolio focus underway.CPR
Q3 202418 Jan 2026 - Resilient 2024 growth and strong cash flow, but margin pressures and tariff risks ahead.CPR
Q4 202410 Dec 2025 - Q1 organic sales fell 4.2%, but APAC growth and cost actions support 2025 guidance.CPR
Q1 202520 Nov 2025 - Solid organic growth and margin resilience achieved despite macro headwinds, leverage at 2.9x.CPR
Q3 202530 Oct 2025 - Q2 organic growth and margin gains drive resilient H1, with guidance and deleveraging on track.CPR
Q2 202530 Oct 2025